Table 2.
Category | Subgroup | RR (95% CI) | P | I 2 |
---|---|---|---|---|
Induction therapy | ||||
Clinical/CDAI-100 response | UC | 1.62 (1.33–1.97) | <.05 | 43% |
CD | 1.49 (1.23–1.80) | <.05 | 2% | |
Mucosal healing | UC | 1.53 (1.21–1.95) | <.05 | 28% |
CD | NA | |||
Maintenance therapy | ||||
Durable clinical remission | UC | 2.12 (1.06–4.25) | <.05 | 0% |
CD | 1.31 (0.86–2.01) | .21 | 0% | |
Clinical/CDAI-100 response | UC | 2.15 (1.56–2.96) | <.05 | 0% |
CD | 1.34 (1.13–1.59) | <.05 | 59% | |
Glucocorticoid-free remission | UC | 2.44 (1.61–3.71) | <.05 | 0% |
CD | 2.09 (1.48–2.94) | <.05 | 0% | |
Safety | ||||
Adverse events | UC | 1.03 (0.97–1.10) | .34 | 47% |
CD | 1.00 (0.92–1.08) | .90 | 13% | |
Disease exacerbation | UC | 0.90 (0.59–1.37) | .63 | 68% |
CD | 0.64 (0.40–1.03) | .07 | 70% | |
Serious adverse events | UC | 1.05 (0.78–1.42) | .08 | 0% |
CD | 1.22 (0.97–1.52) | .08 | 57% | |
Serious infection | UC | 0.68 (0.30–1.51) | .34 | 0% |
CD | 1.12 (0.27–4.71) | .87 | 69% |
CD = Crohn disease, CDAI = CD Activity Index, CI = confidence interval, IBD = inflammatory bowel disease, NA = not applicable, RR = relative risk, UC = ulcerative colitis.